Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Welltower Inc. Common Stock (WELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Welltower Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Welltower Inc. Common Stock trades at $235.46 (market cap $167.30B). The key difference: Welltower Inc. Common Stock is far larger — about 18.8× Kymera Therapeutics Inc. Common Stock's market cap, and Welltower Inc. Common Stock pays a 1.46% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Welltower Inc. Common Stock for 6 Days on average.
| KYMR | WELL | |
|---|---|---|
Market Cap | $8.88B | $167.30B |
Volume | 1,028,790 | 3,257,988 |
Sector | Health | Real Estate |
52-Week High | $127.31 | $252.07 |
52-Week Low | $55.80 | $172.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.27B | $185.05B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WELL trades at $230.14, down 0.07% on the day, with a bullish technical signal supported by moving averages and a strong ADX trend indicator. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Revenue grew to $10.67B in 2025, with net income of $936.85M, and is projected to rise to $12.6B in 2026. Analyst sentiment is strongly positive, with 71.43% buy ratings and a consensus price target of $257.08, indicating potential upside. Recent news highlights strategic acquisitions and positive coverage on senior housing demand trends.
Outlook: WELL benefits from strong demographic tailwinds in senior housing and robust analyst support, but high valuation multiples and earnings volatility pose risks. The stock's current price near support at $226 suggests a cautious entry point, with upside driven by execution on growth projections and sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Welltower Inc. Common Stock
Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →
